Darbepoetin alfa, a long-acting erythropoietin analog, offers novel and delayed cardioprotection for the ischemic heart - PubMed (original) (raw)

Darbepoetin alfa, a long-acting erythropoietin analog, offers novel and delayed cardioprotection for the ischemic heart

Erhe Gao et al. Am J Physiol Heart Circ Physiol. 2007 Jul.

Free article

Abstract

Recent studies from our lab and others have shown that the hematopoietic cytokine erythropoietin (EPO) can protect the heart from ischemic damage in a red blood cell-independent manner. Here we examined any protective effects of the long-acting EPO analog darbepoetin alfa (DA) in a rat model of ischemia-reperfusion (I/R) injury. Rats were subjected to 30-min ischemia followed by 72-h reperfusion. In a dose-response study, DA (2, 7, 11, and 30 mug/kg) or vehicle was administered as a single bolus at the start of ischemia. To determine the time window of potential cardioprotection, a single high dose of DA (30 mug/kg) was given at either the initiation or the end of ischemia or at 1 or 24 h after reperfusion. After 3 days, cardiac function and infarct size were assessed. Acute myocyte apoptosis was quantified by TUNEL staining on myocardial sections and by caspase-3 activity assays. DA significantly reduced infarct size from 32.8 +/- 3.5% (vehicle) to 11.0 +/- 3.3% in a dose-dependent manner, while there was no difference in ischemic area between groups. Treatment with DA as late as 24 h after the beginning of reperfusion still demonstrated a significant reduction in infarct size (17.0 +/- 1.6%). Consistent with infarction data, DA improved in vivo cardiac reserve compared with vehicle. Finally, DA significantly decreased myocyte apoptosis and caspase-3 activity after I/R. These data indicate that DA protects the heart against I/R injury and improves cardiac function, apparently through a reduction of myocyte apoptosis. Of clinical importance pointing toward a relevant therapeutic utility, we report that even if given 24 h after I/R injury, DA can significantly protect the myocardium.

PubMed Disclaimer

Cited by

STAT3 but Not STAT5 Contributes to the Protective Effect of Electroacupuncture Against Myocardial Ischemia/Reperfusion Injury in Mice.
Guo HH, Jing XY, Chen H, Xu HX, Zhu BM. Guo HH, et al. Front Med (Lausanne). 2021 Jul 9;8:649654. doi: 10.3389/fmed.2021.649654. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34307396 Free PMC article.
Myocardial Ablation of G Protein-Coupled Receptor Kinase 2 (GRK2) Decreases Ischemia/Reperfusion Injury through an Anti-Intrinsic Apoptotic Pathway.
Fan Q, Chen M, Zuo L, Shang X, Huang MZ, Ciccarelli M, Raake P, Brinks H, Chuprun KJ, Dorn GW 2nd, Koch WJ, Gao E. Fan Q, et al. PLoS One. 2013 Jun 21;8(6):e66234. doi: 10.1371/journal.pone.0066234. Print 2013. PLoS One. 2013. PMID: 23805205 Free PMC article.
Pretreatment with darbepoetin attenuates renal injury in a rat model of cisplatin-induced nephrotoxicity.
Choi DE, Jeong JY, Lim BJ, Lee KW, Shin YT, Na KR. Choi DE, et al. Korean J Intern Med. 2009 Sep;24(3):238-46. doi: 10.3904/kjim.2009.24.3.238. Epub 2009 Aug 26. Korean J Intern Med. 2009. PMID: 19721861 Free PMC article.
Acute erythropoietin cardioprotection is mediated by endothelial response.
Teng R, Calvert JW, Sibmooh N, Piknova B, Suzuki N, Sun J, Martinez K, Yamamoto M, Schechter AN, Lefer DJ, Noguchi CT. Teng R, et al. Basic Res Cardiol. 2011 May;106(3):343-54. doi: 10.1007/s00395-011-0158-z. Epub 2011 Feb 23. Basic Res Cardiol. 2011. PMID: 21347618 Free PMC article.
Raves and risks for erythropoietin.
Maiese K, Chong ZZ, Shang YC. Maiese K, et al. Cytokine Growth Factor Rev. 2008 Apr;19(2):145-55. doi: 10.1016/j.cytogfr.2008.01.004. Epub 2008 Mar 4. Cytokine Growth Factor Rev. 2008. PMID: 18299246 Free PMC article. Review.

Darbepoetin alfa, a long-acting erythropoietin analog, offers novel and delayed cardioprotection for the ischemic heart - PubMed (original) (raw)